Nykredit A S purchased a new stake in shares of Ventas, Inc. (NYSE:VTR – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,738 shares of the real estate investment trust’s stock, valued at approximately $11,698,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. NewEdge Advisors LLC boosted its stake in Ventas by 856.1% during the 1st quarter. NewEdge Advisors LLC now owns 7,926 shares of the real estate investment trust’s stock valued at $545,000 after purchasing an additional 7,097 shares during the period. Empowered Funds LLC increased its position in Ventas by 6.8% in the 1st quarter. Empowered Funds LLC now owns 8,373 shares of the real estate investment trust’s stock worth $576,000 after buying an additional 536 shares during the period. Woodline Partners LP increased its position in Ventas by 46.8% in the 1st quarter. Woodline Partners LP now owns 36,826 shares of the real estate investment trust’s stock worth $2,532,000 after buying an additional 11,739 shares during the period. Focus Partners Wealth lifted its holdings in shares of Ventas by 130.4% during the first quarter. Focus Partners Wealth now owns 21,613 shares of the real estate investment trust’s stock worth $1,486,000 after buying an additional 12,233 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Ventas in the second quarter valued at approximately $805,000. 94.18% of the stock is owned by institutional investors and hedge funds.
Ventas Trading Down 2.0%
Shares of VTR stock opened at $90.27 on Friday. The firm has a fifty day moving average of $92.94 and a 200-day moving average of $87.82. The stock has a market cap of $46.30 billion, a price-to-earnings ratio of 167.17, a P/E/G ratio of 3.59 and a beta of 0.70. Ventas, Inc. has a 52-week low of $66.38 and a 52-week high of $101.60. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.44 and a current ratio of 0.44.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on VTR shares. Barclays raised their price objective on shares of Ventas from $99.00 to $102.00 and gave the stock an “equal weight” rating in a research note on Monday. Raymond James Financial assumed coverage on shares of Ventas in a research report on Tuesday, June 16th. They issued an “outperform” rating and a $94.00 price target on the stock. Jefferies Financial Group upped their price objective on shares of Ventas from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. JPMorgan Chase & Co. boosted their price target on Ventas from $93.00 to $94.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company raised their price objective on Ventas from $96.00 to $104.00 and gave the stock an “overweight” rating in a research report on Tuesday. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $99.00.
Check Out Our Latest Stock Analysis on VTR
Ventas Profile
Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas’ business model combines property ownership with active asset management and capital markets activity.
See Also
- Five stocks we like better than Ventas
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR – Free Report).
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.
